preliminary evaluations related to the ranges of hematological and biochemical variables in hospitalized patients with stroke

background: according to the international reports, brain stroke is the main reason of death and disability. in ischemic stroke, early and precise classification of patients who may profit from conflicting finest therapeutic interference is necessary if enhanced effects in terms of survival are to be talented. due to uncomplicated, easy performance, and inexpensive method the aim of this preliminary study was to investigate changes related to biochemical and hematological variables in patients with stroke. methods: a cross‑sectional study located at the neurology ward of the ayatolah kashani and alzahra hospitals’ (conducted to isfahan neurosciences research center) was carried out on fifty patients (females; n = 20 and males; n = 30) between april 1, 2012 and september 31, 2012. the data from subjects’ records were taken for analyzing variables. the statistical analysis of d‑base was performed using (spss) for windows. results: analysis of available data showed that with a mean of 182.4 mg/dl, blood sugar (bs) ranged from 75 to 300 mg/dl ( n = 15/50). the changes in hemoglobin (hgb) (mean 4.6 g/dl, n = 27/50), platelet (mean 210, 653/mm3, n = 26/50) and lymphocyte (lymph) (mean 37, n = 26/50) seems to be significant. the mean age of females was 76 years (ranged 46‑93 years). the mean age of males was 70 years (ranged 31-90 years). information related to previous drug history was available only in 24 patients. in 5 out of 22 cases ischemic heart disease (ihd) were positive. in 8 out of 29 cases, diabetes mellitus was positive. in 5 out of 28 cases, hypertension (htn) was positive. in the four patients both ihd and htn were positive. conclusions: any considerable alter in patients’ biochemical and hematological figures (bs, hgb, plt and lymph) may necessitate further attention related to inter‑ and intra‑individual variability in clinical supervision and drug’s assortment. therefore, success in treatment could be achieved by the close management of clinical, biochemical, hematological, and pharmacological manifestation. to reduce disability, mortality, and morbidity in iranian stroke population further clinical studies are needed to correlate drugs and laboratory markers to associated clinical events in order.